Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NYSE:BHVN NASDAQ:EPRX NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.46+2.6%$29.34$22.24▼$46.00$1.75B0.59860,379 shs1.14 million shsBHVNBiohaven$11.34-0.2%$10.00$7.48▼$18.57$1.70B1.352.82 million shs2.36 million shsEPRXEupraxia Pharmaceuticals$6.04+0.2%$6.97$3.85▼$9.32$392.71M0.97298,180 shs141,123 shsNUVBNuvation Bio$4.91+3.0%$4.73$1.57▼$9.75$1.71B1.524.41 million shs5.25 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.58%+4.14%+2.40%+5.78%-14.39%BHVNBiohaven-0.02%+4.61%+25.14%+18.53%-27.50%EPRXEupraxia Pharmaceuticals+0.17%+1.51%-20.00%-17.93%+53.69%NUVBNuvation Bio+2.72%+1.87%+2.51%+10.57%+122.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$29.46+2.6%$29.34$22.24▼$46.00$1.75B0.59860,379 shs1.14 million shsBHVNBiohaven$11.34-0.2%$10.00$7.48▼$18.57$1.70B1.352.82 million shs2.36 million shsEPRXEupraxia Pharmaceuticals$6.04+0.2%$6.97$3.85▼$9.32$392.71M0.97298,180 shs141,123 shsNUVBNuvation Bio$4.91+3.0%$4.73$1.57▼$9.75$1.71B1.524.41 million shs5.25 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals+2.58%+4.14%+2.40%+5.78%-14.39%BHVNBiohaven-0.02%+4.61%+25.14%+18.53%-27.50%EPRXEupraxia Pharmaceuticals+0.17%+1.51%-20.00%-17.93%+53.69%NUVBNuvation Bio+2.72%+1.87%+2.51%+10.57%+122.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$40.8938.79% UpsideBHVNBiohaven 2.71Moderate Buy$22.2796.30% UpsideEPRXEupraxia Pharmaceuticals 2.89Moderate Buy$18.33203.53% UpsideNUVBNuvation Bio 2.55Moderate Buy$12.50154.84% UpsideCurrent Analyst Ratings BreakdownLatest EPRX, AGIO, NUVB, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$36.00 ➝ $31.006/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026BHVNBiohaven Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/29/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$41.00 ➝ $40.005/27/2026BHVNBiohaven Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy5/26/2026BHVNBiohaven HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.005/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/21/2026EPRXEupraxia Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.005/13/2026BHVNBiohaven Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.005/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M32.43N/AN/A$20.46 per share1.44BHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/ANUVBNuvation Bio$62.90M27.15N/AN/A$0.88 per share5.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%7/30/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)EPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%8/11/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)Latest EPRX, AGIO, NUVB, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/19/2026Q4 2025EPRXEupraxia Pharmaceuticals-$0.16-$0.37-$0.21-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59BHVNBiohaven1.877.417.41EPRXEupraxia Pharmaceuticals0.0219.3119.31NUVBNuvation Bio0.157.447.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ABHVNBiohaven88.78%EPRXEupraxia PharmaceuticalsN/ANUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%BHVNBiohaven13.80%EPRXEupraxia PharmaceuticalsN/ANUVBNuvation Bio30.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableEPRXEupraxia Pharmaceuticals2965.02 millionN/AN/ANUVBNuvation Bio60348.20 million243.36 millionOptionableEPRX, AGIO, NUVB, and BHVN HeadlinesRecent News About These CompaniesNuvation Bio (NYSE:NUVB) Director Robert Mashal Purchases 25,000 SharesJune 12 at 6:57 AM | insidertrades.comNuvation Bio (NYSE:NUVB) Shares Gap Up - Here's WhyJune 9, 2026 | marketbeat.comNuvation Bio: Buy The Ibtrozi Launch (Rating Upgrade)June 8, 2026 | seekingalpha.comNuvation Bio (NUVB) Presents Outcomes from TRUST-II StudyJune 6, 2026 | insidermonkey.comNuvation Bio Inc. (NYSE:NUVB) Receives Average Rating of "Moderate Buy" from BrokeragesJune 3, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Nuvation Bio (NUVB), Universal Health (UHS)May 28, 2026 | theglobeandmail.comNuvation Bio Shareholders Approve Directors and Executive CompensationMay 27, 2026 | tipranks.comNuvation Bio to Present at the Jefferies Global Healthcare ConferenceMay 27, 2026 | prnewswire.comNuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual MeetingMay 27, 2026 | prnewswire.comNuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 25, 2026 | seekingalpha.comNuvation Bio Insider Trading Activity | NYSE:NUVB | BenzingaMay 24, 2026 | benzinga.comNuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference TranscriptMay 22, 2026 | seekingalpha.comNuvation Bio (NUVB) Collaborates with Thermo FisherMay 22, 2026 | insidermonkey.comUBS Group AG Reduces Stake in Nuvation Bio Inc. $NUVBMay 21, 2026 | marketbeat.comNuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA StepsMay 18, 2026 | finance.yahoo.comNuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung CancerMay 13, 2026 | prnewswire.comNuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comIs Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?May 13, 2026 | insidermonkey.comNuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesMay 8, 2026 | finance.yahoo.comNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small ...May 8, 2026 | uk.finance.yahoo.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)May 7, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEPRX, AGIO, NUVB, and BHVN Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$29.46 +0.74 (+2.58%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$28.80 -0.66 (-2.24%) As of 06/12/2026 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Biohaven NYSE:BHVN$11.34 -0.03 (-0.24%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$11.40 +0.06 (+0.52%) As of 06/12/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Eupraxia Pharmaceuticals NASDAQ:EPRX$6.04 +0.01 (+0.17%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.04 0.00 (0.00%) As of 06/12/2026 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Nuvation Bio NYSE:NUVB$4.90 +0.15 (+3.05%) Closing price 06/12/2026 03:59 PM EasternExtended Trading$5.00 +0.10 (+1.96%) As of 06/12/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
